Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

21. Fluoxetine: possible small risk of congenital cardiac defects

Fluoxetine: possible small risk of congenital cardiac defects Fluoxetine: possible small risk of congenital cardiac defects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fluoxetine: possible small risk of congenital cardiac defects Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to draw conclusions (...) on whether there is a similar risk for other SSRIs. The potential risks should be considered in the context of the benefits of treatment Published 11 December 2014 From: Therapeutic area: , Article date: March 2010 Fluoxetine (brand leader Prozac) is a commonly used antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class of medicines. Depressive symptoms and major depressive disorders occur in pregnant women with prevalence rates ranging from 7% to 20%. Untreated depression

2010 MHRA Drug Safety Update

22. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Statistics from Altmetric.com Question Question Is the antidepressant venlafaxine associated with an increased risk of sudden cardiac death compared with other antidepressants? People The cohort consisted of 207 384 new users of venlafaxine, fluoxetine, citalopram or dosulepin

2010 Evidence-Based Mental Health

23. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine

2010 Evidence-Based Mental Health

24. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis

Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Yi ZM, Liu F, Zhai SD CRD summary This review found that fluoxetine reduced incidence of newly diagnosed depression in patients with stroke, but did not reduce the symptom severity of post-stroke depression (...) . The authors’ conclusion on the benefits of fluoxetine is likely to be reliable, but the conclusion on symptom severity was influenced by extensive variation in the included trials. Authors' objectives To assess the prophylactic efficacy and safety of fluoxetine for post-stroke depression in patients with stroke. Searching Sixteen databases, including PubMed, EMBASE, the Cochrane Library and Chinese databases were searched up to December 2009 for relevant studies published in English or Chinese; search

Full Text available with Trip Pro

2010 DARE.

25. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Lenox-Smith A, Greenstreet L, Burslem K, Knight C Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of venlafaxine versus either generic fluoxetine or generic amitriptyline for the first-line treatment of patients with major depressive disorder. The authors concluded that, despite its relatively high

2009 NHS Economic Evaluation Database.

26. Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression

Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression

2008 Evidence-Based Mental Health

27. Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression

Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents

2008 Evidence-Based Mental Health

28. Light therapy and fluoxetine similarly effective for improving seasonal affective disorder

Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Light therapy and fluoxetine similarly effective for improving seasonal affective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Article Text Therapeutics Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Statistics

2008 Evidence-Based Mental Health

29. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine

Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Article Text Therapeutics Combined

2008 Evidence-Based Mental Health

30. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

2008 NHS Economic Evaluation Database.

31. Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

2007 Evidence-Based Mental Health

32. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. (PubMed)

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin.Retrospective cohort study.UK General Practice Research Database.219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005.Completed suicide and attempted suicide.Venlafaxine users had (...) a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared with dothiepin were 2.54 (1.07

Full Text available with Trip Pro

2007 BMJ

33. Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment

Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Article Text

2007 Evidence-Based Mental Health

34. Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder

Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Article Text Therapeutics Continuing fluoxetine treatment may delay

Full Text available with Trip Pro

2006 Evidence-Based Mental Health

35. Fluoxetine improves minor depressive disorders

Fluoxetine improves minor depressive disorders Fluoxetine improves minor depressive disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine improves minor depressive disorders Article Text Therapeutics Fluoxetine improves minor depressive disorders Free Philip J Cowen , MD, FRCPsych Statistics from Altmetric.com Judd LL, Rapaport MH, Yonkers KA, et al . Randomized, placebo-controlled trial of fluoxetine for acute treatment

Full Text available with Trip Pro

2006 Evidence-Based Mental Health

36. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Article Text Treatment Fluoxetine plus cognitive behavioural therapy

Full Text available with Trip Pro

2006 Evidence-Based Nursing

37. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Article Text Therapeutics Fluoxetine plus cognitive

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

38. Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents

Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents Article Text Therapeutics Fluoxetine plus cognitive behavioural therapy

Full Text available with Trip Pro

2006 Evidence-Based Mental Health

39. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

40. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. (PubMed)

Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. Antidepressant medication is frequently prescribed for patients with anorexia nervosa.To determine whether fluoxetine can promote recovery and prolong time-to-relapse among patients with anorexia nervosa following weight restoration.Randomized, double-blind, placebo-controlled trial. From January 2000 until May 2005, 93 patients with anorexia nervosa received intensive inpatient or day-program treatment (...) at the New York State Psychiatric Institute or Toronto General Hospital. Participants regained weight to a minimum body mass index (calculated as weight in kilograms divided by the square of height in meters) of 19.0 and were then eligible to participate in the randomized phase of the trial.Participants were randomly assigned to receive fluoxetine or placebo and were treated for up to 1 year as outpatients in double-blind fashion. All patients also received individual cognitive behavioral therapy.The

Full Text available with Trip Pro

2006 JAMA